The company is a leading pharmaceutical company. Its business covers the development, production, marketing and sale of non-patent medicines and proprietary Chinese medicines. According to Frost & Sullivan, the company is the largest non-patent pharmaceutical company in Hong Kong, and its share of the entire Hong Kong non-patent drug market has exceeded 30% every year since 2012. According to Frost & Sullivan, every year since 2012, the company has (i) been the hospital authority's largest supplier of nonpatent drugs, accounting for more than 70% of the annual procurement value of the Hospital Authority's nonproprietary medicines in the relevant years; and (ii) operating with the Non-Hospital Authority as the largest non-patent drug supplier in Hong Kong, with a market share of over 20%. For the years ended March 31, 2014, 2015 and 2016, the Company's revenue categories were approximately $926.18 million, $947.59 million and $1,0883.86 million; for the same period, the company's net profit categories were approximately $172.36 million, $101.90 million and $145.61 million. The intended use of the proceeds assumes that the overallotment rights have not been exercised. Based on the median offer price of HK$1.50 per share, it is estimated that the net proceeds from the sale of shares are approximately HK$600.6 million. The Board of Directors intends to use the net proceeds for the following purposes: